CoChat
Sign Up
Cited by 24

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Bexarotene Reduces Blood-Brain Barrier Permeability in Cerebral Ischemia-Reperfusion Injured Rats

Xu, Lu, Cao, Fang, Xu, Feng, He, Baicheng, Dong, Zhi·2015·PLOS ONE
DOI 10.1371/journal.pone.0122744PMC PMC4386818
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0122744

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 26

  1. T Yamashita, 2011, Therapeutic approaches to vascular protection in ischemic stroke, Acta Med Okayama, 65, 219
  2. RM Adibhatla, 2008, Tissue plasminogen activator (tPA) and matrix metalloproteinases in the pathogenesis of stroke: therapeutic strategies, CNS Neurol Disord Drug Targets, 7, 243, 10.2174/187152708784936608 · DOI
  3. EC Vonderheid, 2003, Treatment planning in cutaneous T-cell lymphoma, Dermatol Ther, 16, 276, 10.1111/j.1396-0296.2003.01638.x · DOI
  4. J Fu, 2011, In vitro anti-angiogenic properties of LGD1069, a selective retinoid X-receptor agonist through down-regulating Runx2 expression on Human endothelial cells, BMC Cancer, 11, 227, 10.1186/1471-2407-11-227 · DOI
  5. EZ Longa, 1989, Reversible middle cerebral artery occlusion without craniectomy in rats, Stroke, 20, 84, 10.1161/01.STR.20.1.84 · DOI · Paper page
  6. M Zheng, 2014, ApoE-deficient promotes blood-brain barrier disruption in experimental autoimmune encephalomyelitis via alteration of MMP-9, J Mol Neurosci, 54, 282, 10.1007/s12031-014-0291-x · DOI
  7. M Asahi, 2001, Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia, J Neurosci, 21, 7724, 10.1523/JNEUROSCI.21-19-07724.2001 · DOI · Paper page
  8. F Chen, 2009, Disruptions of occludin and claudin-5 in brain endothelial cells in vitro and in brains of mice with acute liver failure, Hepatology, 50, 1914, 10.1002/hep.23203 · DOI
  9. H Xin, 2012, Relationship of gelatinases-tight junction proteins and blood-brain barrier permeability in the early stage of cerebral ischemia and reperfusion, Neural Regen Res, 7, 2405
  10. AW Clark, 1997, Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia, Neurosci Lett, 238, 53, 10.1016/S0304-3940(97)00859-8 · DOI
  11. JH Heo, 1999, Matrix metalloproteinases increase very early during experimental focal cerebral ischemia, J Cereb Blood Flow Metab, 19, 624, 10.1097/00004647-199906000-00005 · DOI
  12. D Shimbo, 2014, Post-ischemic intra-arterial infusion of liposome-encapsulated hemoglobin can reduce ischemia reperfusion injury, Brain Res, 1554, 59, 10.1016/j.brainres.2014.01.038 · DOI
  13. Y Liu, 2014, The protective effect of HET0016 on brain edema and blood-brain barrier dysfunction after cerebral ischemia/reperfusion, Brain Res, 1544, 45, 10.1016/j.brainres.2013.11.031 · DOI
  14. Y Wu, 2014, Neuroprotection by platelet-activating factor acetylhydrolase in a mouse model of transient cerebral ischemia, Neurosci Lett, 558, 26, 10.1016/j.neulet.2013.09.005 · DOI
  15. Y Akamatsu, 2011, Stachybotrys microspora triprenyl phenol-7, a novel fibrinolytic agent, suppresses superoxide production, matrix metalloproteinase-9 expression, and thereby attenuates ischemia/reperfusion injury in rat brain, Neurosci Lett, 503, 110, 10.1016/j.neulet.2011.08.018 · DOI
  16. JR Lynch, 2001, Apolipoprotein E modulates glial activation and the endogenous central nervous system inflammatory response, J Neuroimmunol, 114, 107, 10.1016/S0165-5728(00)00459-8 · DOI
  17. L Lomnitski, 1999, Antioxidant mechanisms in apolipoprotein E deficient mice prior to and following closed head injury, Biochim Biophys Acta, 1453, 359, 10.1016/S0925-4439(99)00010-1 · DOI
  18. S Zhou, 2013, Apolipoprotein E protects astrocytes from hypoxia and glutamate-induced apoptosis, FEBS Lett, 587, 254, 10.1016/j.febslet.2012.12.003 · DOI
  19. K Nishitsuji, 2011, Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an in vitro blood-brain barrier model, J Biol Chem, 286, 17536, 10.1074/jbc.M111.225532 · DOI · Paper page
  20. JR Lynch, 2002, Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema, Ann Neurol, 51, 113, 10.1002/ana.10098 · DOI · Paper page
  21. SM Fullerton, 2001, Impairment of the blood-nerve and blood-brain barriers in apolipoprotein e knockout mice, Exp Neurol, 169, 13, 10.1006/exnr.2001.7631 · DOI · Paper page
  22. K Horsburgh, 2000, Intraventricular infusion of apolipoprotein E ameliorates acute neuronal damage after global cerebral ischemia in mice, J Cereb Blood Flow Metab, 20, 458, 10.1097/00004647-200003000-00003 · DOI
  23. JD Ulrich, 2013, In vivo measurement of apolipoprotein E from the brain interstitial fluid using microdialysis, Mol Neurodegener, 8, 13, 10.1186/1750-1326-8-13 · DOI · Paper page
  24. K McFarland, 2013, Low dose bexarotene treatment rescues dopamine neurons and restores behavioral function in models of Parkinson's disease, ACS Chem Neurosci, 4, 1430, 10.1021/cn400100f · DOI
  25. V Lerner, 2013, The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial, J Clin Psychiatry, 74, 1224, 10.4088/JCP.12m08160 · DOI
  26. V Bomben, 2014, Bexarotene reduces network excitability in models of Alzheimer's disease and epilepsy, Neurobiol Aging, 35, 2091, 10.1016/j.neurobiolaging.2014.03.029 · DOI

Cited by

Sorted by citations

Metadata

Authors
Xu, L., Cao, F., Xu, F., He, B., & Dong, Z.
Venue
PLOS ONE
Publisher
Public Library of Science (PLoS)
Published
2015-04-06
Volume
10
Issue
4
Pages
e0122744
ISSN
1932-6203
DOI
10.1371/journal.pone.0122744
PMC
PMC4386818
Cited by
24
References
4
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review